Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02344303 · ClinicalTrials.gov registry record · Phase 1
Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals
A Phase 1 study, sponsored by Trevena.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT02344303 is a Phase 1 study that has completed, run by Trevena. The registered enrollment target is 63 participants.
The verdict
NCT02344303, a Phase 1 study, has completed, sponsored by Trevena.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
Assess the electrocardiogram effects of TRV130 relative to placebo at therapeutic and supratherapeutic doses.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG TRV130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02344303
The ClinicalTrials.gov registry entry for NCT02344303 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trevena, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02344303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02344303 about?
NCT02344303 is a clinical study titled "Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals". Assess the electrocardiogram effects of TRV130 relative to placebo at therapeutic and supratherapeutic doses.
What is the current status of trial NCT02344303?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2014-12. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02344303?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), TRV130 (DRUG).
Who is sponsoring clinical trial NCT02344303?
This trial is sponsored by Trevena, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.